Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Leukemia, Myeloid, Chronic-Phase 4Philadelphia Chromosome 3Leukemia 3Breast Neoplasms 3Bronchiolitis Obliterans Syndrome 2Translocation, Genetic 1Pathologic Processes 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1Leukemia, Myeloid 1Hematologic Diseases 1Glioblastoma 1Bone Marrow Diseases 1Blast Crisis 1Advanced Breast Cancer (Parts 1 and 2) 1

Interventions

bosutinib 1Imatinib Mesylate 1Cholecalciferol 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pathologic Processes × bosutinib × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡